New basal insulin for adults with type 1 or type 2 diabetes

Objective: To review 2 new basal insulin analogs that have been approved in the United States for use in type 1 and type 2 diabetes—insulin glargine 300 units/mL and insulin degludec 100 units/mL and 200 units/mL. Data Sources: PubMed was searched using the terms “insulin glargine 300 units/mL,” “Gla-300,” “insulin degludec,” “IDeg,” “insulin degludec 200 units/mL,” and “insulin degludec 100 units/mL” for articles published between 1995 and May 2016. Study Selection and Data Extraction: Clinical trials, meta-analyses and subanalyses were identified; review articles were excluded. Relevant citations from identified articles were also reviewed. Data Synthesis: The new basal insulins, insulin glargine 300 units/mL and insulin degludec 100 units/mL and 200 units/mL, have improved pharmacokinetic and pharmacodynamic profiles compared to insulin glargine 100 units/mL. All demonstrate longer durations of action, beyond 24 hours, and less variability. These improved profiles translate into comparable A1C reductions and comparable, or improved, levels of hypoglycemia compared to insulin glargine 100 units/mL. Conclusions: These benefits may lead to improved glycemic control in a range of patients with type 1 and type 2 diabetes with true once-daily dosing.

Download Full-text

Long-Term Efficacy of Insulin Glargine After Switching from NPH Insulin as Intensive Replacement of Basal Insulin in Japanese Diabetes Mellitus. Comparison of Efficacy between Type 1 and Type 2 diabetes (JUN-LAN Study 1.2)

Endocrine Journal ◽

10.1507/endocrj.k07e-035 ◽

2007 ◽

Vol 54 (6) ◽

pp. 975-983 ◽

Cited By ~ 8

Author(s):

Yoshie KANAZAWA ◽

Yasuhiro IGARASHI ◽

Koji KOMIYA ◽

Yuko SAKURAI ◽

Tomoaki SHIMIZU ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Insulin Glargine ◽

Basal Insulin ◽

Nph Insulin ◽

Term Efficacy

Download Full-text

Insulin Detemir—A New Basal Insulin Analog

Annals of Pharmacotherapy ◽

10.1345/aph.1e334 ◽

2005 ◽

Vol 39 (3) ◽

pp. 502-507 ◽

Cited By ~ 31

Author(s):

Jennifer D Goldman-Levine ◽

Karen W Lee

Keyword(s):

Type 2 Diabetes ◽

Basal Insulin ◽

Insulin Detemir ◽

Data Extraction ◽

Safety Data ◽

Clinical Trial Data ◽

Insulin Analog ◽

Study Selection

OBJECTIVE: To review the pharmacology, pharmacokinetics, clinical trial data, adverse effects, and role in therapy of insulin detemir. DATA SOURCES: Articles and meeting abstracts were identified through searches of MEDLINE (1996–June 2004), EMBASE (1980–June 2004), and International Pharmaceutical Abstracts (1970–June 2004) databases, and unpublished information was provided by the manufacturer. STUDY SELECTION AND DATA EXTRACTION: All available studies relating to insulin detemir's pharmacology were selected. Only human studies were used for pharmacokinetic, drug interaction, efficacy, and safety data. DATA SYNTHESIS: Insulin detemir is a basal insulin analog that has been shown to improve glycemic control in patients with type 1 and type 2 diabetes. CONCLUSIONS: Insulin detemir offers some benefits over NPH for use as basal insulin in patients with type 1 and type 2 diabetes.

Download Full-text